search button
Open Access

Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance

  • Authors:
    • Anja Bukovac
    • Anja Kafka
    • Reno Hrašćan
    • Tomislav Vladušić
    • Nives Pećina‑Šlaus

  • View Affiliations

  • Published online on: October 15, 2019     https://doi.org/10.3892/mco.2019.1936
  • Pages: 563-572

  • Copyright: © Bukovac et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to identify TP53 exon 4 mutations in patients with meningioma and to investigate their potential association with specific tumor pathology. Nucleotide alterations were investigated in 48 meningiomas via the direct sequencing of TP53 exon 4 in patient tumor and blood samples using the DNA Sanger method with the BigDyeTerminator v3.1 Cycle Sequencing kit and Applied Biosystems 3730XL apparatus. The results revealed that TP53 exon 4 was frequently altered in meningioma, occurring in 60.4% of the patients investigated. A total of 18 different alterations were detected in the meningioma samples assessed in the current study. The majority of these appeared more than once and some were repeatedly identified in several patients. Changes at codons 72 (c.215G>C) and 62 (c.186delA) were highly prevalent, occurring in 44.8% of patients. Other changes detected via frequency analysis included: Five substitutions on codon 105 (c.315C>T); four insertions on codon 70 (c.209_210insG); three insertions on codon 64 (c.190C>G), 82 (245C>T; 245delC; 243_244insA) and 104 (c.312G>A); and two insertions on codons 108 (c.322G>C), 71 (c.213C>A), 73 (c.217G>A), 91 (c.271T>C) and 100 (c.300G>T). Codons 68 (c.202_203insT), 77 (c.229C>T), 88 (c.263C>G) and 92 (c.276C>A) were altered once. Alterations on codons 82, 91, 108, 104, 105, 70 and 92 were characterized as possibly damaging by PolyPhen‑2 and Mutation Taster2 tools. The current study also demonstrated that nucleotide alterations were significantly associated with the loss of p53 expression (P=0.04) and female patients (P=0.049), particularly codon 72. The results present novel data on the mutational spectrum of TP53 in meningeal brain tumors.
View Figures
View References

Related Articles

Journal Cover

December-2019
Volume 11 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.4
  • Ranked
    (total number of cites)
  • CiteScore: 2.8
  • CiteScore Rank: Q3: #250/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.55
  • SCImago Journal Rank (SJR): 0.446
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Bukovac A, Kafka A, Hrašćan R, Vladušić T and Pećina‑Šlaus N: Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance. Mol Clin Oncol 11: 563-572, 2019.
APA
Bukovac, A., Kafka, A., Hrašćan, R., Vladušić, T., & Pećina‑Šlaus, N. (2019). Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance. Molecular and Clinical Oncology, 11, 563-572. https://doi.org/10.3892/mco.2019.1936
MLA
Bukovac, A., Kafka, A., Hrašćan, R., Vladušić, T., Pećina‑Šlaus, N."Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance". Molecular and Clinical Oncology 11.6 (2019): 563-572.
Chicago
Bukovac, A., Kafka, A., Hrašćan, R., Vladušić, T., Pećina‑Šlaus, N."Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance". Molecular and Clinical Oncology 11, no. 6 (2019): 563-572. https://doi.org/10.3892/mco.2019.1936